Credit Suisse analyst Erin Wright maintained a Buy rating on Align Tech (ALGN) on October 23 and set a price target of $320.00. The company’s shares closed last Monday at $243.38.
According to TipRanks.com, Wright is a 5-star analyst with an average return of 9.5% and a 64.2% success rate. Wright covers the Services sector, focusing on stocks such as Fulgent Genetics Inc, Charles River Labs, and Medpace Holdings.
Align Tech has an analyst consensus of Moderate Buy, with a price target consensus of $263.00, representing a 7.0% upside. In a report issued on October 17, Stifel Nicolaus also reiterated a Buy rating on the stock with a $290.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $334.64 and a one-year low of $169.84. Currently, Align Tech has an average volume of 1.46M.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Align Technology, Inc. engages in the manufacture, design, and marketing of global medical devices. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen and assist products, and vivera retainers along with training and ancillary products for treating malocclusion.
